Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and only partially reversible symptoms. Worldwide, the incidence of COPD presents a disturbing continuous increase. Anxiety and depression are remarkably common in COPD patients, but the evidence about optimal approaches for managing psychological comorbidities in COPD remains unclear and largely speculative. Pharmacological treatment based on selective serotonin reuptake inhibitors has almost replaced tricyclic antidepressants. The main psychological intervention is cognitive behavioral therapy. Of particular interest are pulmonary rehabilitation programs, which can reduce anxiety and depressive symptoms in these patients. Although the literature on treating anxiety and depression in patients with COPD is limited, we believe that it points to the implementation of personalized strategies to address their psychopathological comorbidities.
Introduction
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines chronic obstructive pulmonary disease (COPD) as a disease state characterized by exposure to noxious agents resulting in airflow limitation that is not fully reversible, causing shortness of breath and significant systemic effects. 1 This definition covers a spectrum of respiratory diseases, and includes both the clinical diagnosis of chronic bronchitis and the pathological diagnosis of emphysema. 2 In clinical practice, COPD is defined by characteristically diminished air flow in lung function tests. Spirometry is required to make the diagnosis and staging in this clinical context; 3 the presence of a postbronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV 1 /FVC) 0. 70 confirms the presence of persistent airflow limitation and thus of COPD. Unlike asthma, the limitation is practically irreversible and usually worsens gradually over time. 4 This worsening is causally related to an abnormal inflammatory response of the lungs to inhaled harmful particles or gases, attributed -usually -to smoking. 5 COPD is a leading cause of morbidity and mortality worldwide and results in an economic and social burden that is both substantial and increasing. 6 COPD prevalence, morbidity, and mortality vary across countries and across different groups within countries. The Global Burden of Disease Study estimated that COPD will become the fourth leading cause of death and the seventh leading cause of disability-adjusted life year(s) lost worldwide by 2030. 7 The death rate associated with COPD has doubled in the past 30 years, 8 implying that the health-care system failed to address the problem. 9 Comorbidity studies [10] [11] [12] from Western and developing countries, inpatient and outpatient population, and younger and elderly patients reveal a substantial overrepresentation of anxiety and depression in COPD, from significant symptoms to full diagnostic mental disorders, 13 according to Diagnostic and Statistical Manual of Mental Disorders-4th edition (DSM-IV) and International Classification of Diseases, 10th Revision (ICD-10) taxonomic systems. Prevalence rates of both anxiety and depression in patients with COPD vary widely depending on the population surveyed and the measurement tools. Also, the overlap between symptoms of COPD disease and symptoms of anxiety and depression may contribute to the variations in prevalence figures, especially because questionnaires designed to screen for anxiety and depression include a large number of somatic complaints (poor sleeping pattern, anorexia, breathlessness, and fatigue). 14 Anxiety in COPD patients is often associated with clinical depression, and studies indicate that depressed COPD patients have a seven-fold risk to suffer from comorbid clinical anxiety compared to nondepressed COPD patients. 11, 15 There is an overlap in existing symptomatology between the two disorders, with fatigue, weight changes, sleep disturbance, agitation, irritability, and difficulty in concentrating appearing as common symptoms. 16 In outpatients with COPD, studies indicate rates of depression varying from 7% to 80% and that of anxiety from 2% to 80%. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Prevalence of generalized anxiety disorder (GAD) ranges from 10% to 33% 27, 28 and of panic attacks or panic disorder (PD) from 8% to 67%. 28 In stable COPD, the prevalence of clinical depression ranges from 10% to 42% and that of anxiety between 10% and 19%. 29 In a systematic review 30 that focused on patients with severe COPD disease, the prevalence of depression ranged from 37% to 71% and that of anxiety from 50% to 75%, figures comparable to or higher than prevalence rates in other advanced diseases such as cancer, HIV, heart disease, and renal disease.
Comorbid psychological impairments in COPD patients predict increased functional impairment, 15 ,31 disability 17 and morbidity, 32, 33 lower quality of life, 34, 35 and decreased adherence to the treatment. 36, 37 A systematic review and a metaanalysis have shown that depression and anxiety increase the risk of hospitalization for COPD patients. 9, 38 Also, patients with comorbidity spend twice as long time in hospitals and have increased mortality rates. [39] [40] [41] [42] Accordingly, recent consensus statements and guidelines on optimal care for COPD patients emphasize the need for assessment and adequate treatment of persisting anxiety and depressive symptoms in these patients. Despite the high prevalence and considerable negative impact of coexisting psychopathology in COPD, the evidence about optimal approaches for managing depression and anxiety remains unclear and largely speculative.
The objectives of this paper are to provide an overview of the prevalence, impact, and pathophysiology associated with anxiety and depression in patients with COPD and to review studies on pharmacological and nonpharmacological interventions, in an effort to highlight current knowledge and identify needs for future research.
Anxiety in patients with COPD
Anxiety disorder is a generalized term for a variety of abnormal and pathological fear and anxiety states, including GAD, PD, agoraphobia, obsessive-compulsive disorder, phobic disorders, and traumatic stress disorders. Anxiety disorders are defined using established diagnostic criteria, eg, current versions of DSM 43 or ICD 44 criteria, while anxiety symptoms are assessed using formal psychological instruments, eg, Hamilton Anxiety Rating Scale, 45 Beck Anxiety Inventory, 46 and State-Trait Anxiety Inventory. 47 GAD and PD occur at a higher rate in patients with COPD compared with the general population. 48 Symptoms of anxiety are manifested in a variety of ways, including physiological signs of arousal, such as tachycardia, sweating, and dyspnea. Anxiety in patients with COPD is intimately linked with the fear of acute dyspnea attacks and essentially with the sense of suffocation and the fear of death. [49] [50] [51] The prevalence of anxiety-related disorders in COPD is associated with reduced functional ability and rehospitalizations. 52 Common mechanisms for explaining this high association include factors related to smoking and dyspnea. Smoking is widely acknowledged as the most important environmental risk factor for the development of COPD, 53 and high levels of anxiety have been identified as a risk factor for the initiation of smoking. 54, 55 Thus people who develop COPD as a consequence of smoking probably experienced higher levels of anxiety than the general population prior to developing the disease, and moreover, these individuals may have a greater tendency to addiction since nicotine withdrawal is associated with greater symptoms of anxiety. [56] [57] [58] Evidence also suggests pathophysiologic relationships among dyspnea, hyperventilation, and anxiety. 49 Physiological research has demonstrated both that respiratory rate is increased by anxiety and that the resulting rapid, shallow breathing pattern markedly worsens dyspnea in COPD. 59, 60 The key common physiological factors in COPD are increased ventilatory load, reduced ventilatory capacity, and increased neural respiratory drive, hyperinflation, and neuromechanical dissociation, leading to an efferent-afferent mismatch, which is fundamental to the origin of dyspnea. 61 When the sense of heightened effort increases beyond Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
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Strategies to improve anxiety and depression in patients with COPD a certain threshold and/or the dissociation between neural drive and the mechanical response reaches a critical level (which likely varies between individuals), it will generate a strong emotional reaction (ie, fear, distress, and anxiety) in the individual, which in turn will precipitate conditioned behavioral (avoidance) responses. 62, 63 These strategies help to attenuate neuromechanical dissociation and to allay anxiety. In some patients these compensations are not possible, and the affective response can quickly escalate to overt panic and overwhelming feelings of lack of control. 64 Extreme fear and foreboding will, in turn, trigger patterned ventilatory and circulatory responses (via sympathetic nervous system activation) that can further amplify respiratory discomfort. The vicious cycle of breathlessness and anxiety conceptualized as "dyspnea-anxiety-dyspnea cycle" relationship suggests patients' emotional response to breathlessness exacerbates their perception of breathlessness. 65 This cycle can be illustrated by the cognitive behavioral model of dyspnea, hyperventilation, and anxiety. 49 This positive feedback cycle states that individuals may misinterpret physical sensations such as dyspnea, leading to anxiety, further autonomic arousal, and increased dyspnea. 66, 67 Other theories proposed to explain the overlap of anxiety and panic attack symptoms with COPD are the hyperventilation model and the carbon dioxide hypersensitivity model. Hyperventilation in excess of metabolic need leads to a decrease in pCO 2 , causing a respiratory alkalosis that leads to vasoconstriction and typical panic symptoms such as light-headedness, numbness, tingling sensations, and shortness of breath, in healthy individuals. 60 In COPD patients, increased frequency of breathing predisposes to dynamic hyperinflation, due to the slow time constant for lung deflation. Hyperinflation increases the elastic load, work, and effort of breathing, reduces inspiratory reserve capacities, and exacerbates dyspnea. 68 In patients with severe COPD, chronic hypoventilation induces hypercapnia. 60 An increase in pCO 2 levels has been shown to activate medullary chemoreceptors, which elicits a panic response by activating noradrenergic neurons in the locus ceruleus. 95 Lactate acid, formed because of hypoxia is also linked to panic attacks, and evidence suggests that patients with both COPD and anxiety are hypersensitive to lactic acid and hyperventilation. 49 In other words, the pathogenesis of panic may be related to respiratory physiology by several mechanisms: the anxiogenic effects of hyperventilation, the catastrophic misinterpretation of respiratory symptoms, and/or a neurobiologic sensitivity to CO 2 , lactate, or other signals of suffocation. Consequently, there is a reason to believe that chronic pulmonary disease constitutes a risk factor for the development of panic anxiety related to repeated experiences with dyspnea and life threatening exacerbations of pulmonary dysfunction, repeated episodes of hypercapnia or hyperventilation, the use of anxiogenic medications, and the stress of coping with chronic disease. 69 Anxiety symptoms may distract patients from selfmanagement of disease exacerbations. 70 Even a low intensity dyspnea attack is able to trigger panic anxiety which in turn heightens the sensation of dyspnea and sense of suffocation, thus creating a vicious cycle that forces many patients to restrict their daily activities. [70] [71] [72] Patients with COPD usually describe their understanding of acute dyspnea as an experience inextricably related to anxiety and emotional functioning. As a result, this comorbidity leads to significant decrease in functional capacity, including phobic avoidance of activity because of anticipatory anxiety, further deconditioning, and misuse of anxiogenic medications 73 (β 2 agonists, theophylline, and oral corticosteroids).
Recognition of the presence of this pathophysiological mechanism provides a more comprehensive assessment of the additional functional impairment experienced by the patient even if biological parameters and laboratory results are insufficient to justify the compromised ability to perform physical functions. 15, 21, 52 Sense of loss of control over the disease itself and loss of mastery 74, 75 over their ability to engage in personal and social activities engenders frustration and anxious feelings.
It is important to note that dyspnea at rest or on exertion does not correlate with the magnitude of anxiety-related symptoms, and furthermore, the magnitude of decrease in dyspnea with pharmacotherapy or exercise training is not associated with the reduction in anxiety-related symptoms, this indicates that there are other factors contributing to this relationship. 76 Additionally, although patients with panic report more catastrophic misinterpretations of bodily symptoms, they do not differ from patients without panic on measures of physical functioning, disease severity, shortness of breath, or psychological distress. Thus, it has been suggested that panic symptoms may reflect a cognitive interpretation of pulmonary symptoms rather than objective pulmonary status. 66 Studies indicate that anxiety and depression were not correlated with COPD severity 77 (as determined by FEV 1 % of predicted), and it is reported that dyspnea ratings were influenced by anxiety and depressive symptoms, whereas the physiological state scarcely influenced the anxiety and depressive symptomatology. 78 
Depression in patients with COPD
Today, the ICD-10 44 and DSM-V 79 criteria for depression are the most common diagnostic tools. Different subtypes of depression have been defined, and the clinical course of depression is acknowledged to be variable with patients moving in and out the diagnostic subtypes over time. When it comes to depression in patients with severe somatic illness, the validity of DSM criteria may to a certain degree be questioned because it is difficult to decide when somatic symptoms are secondary to depression, or when they are secondary to somatic illness. 80 Severity of depression is determined by the number and level of symptoms, as well as the degree of functional impairment. Patients with COPD may have a spectrum of symptom severity ranging from short-term depressive symptoms or adjustment disorder with depressed mood to dysthymia up to major depression.
In a cluster of studies that have compared depressive disorders across various chronic illnesses, COPD patients suffer from depression with greater frequency and greater chronicity of mood symptoms. [81] [82] [83] [84] Also, few studies 10, 52 have reported that approximately two-thirds of COPD patients with depression have moderate-to-severe depression, and in one study, 85 it was reported that approximately one-fourth of COPD patients had unrecognized subclinical depression.
Depression in patients with COPD is often marked by feelings of hopelessness and pessimism, reduced sleep, decreased appetite, increased lethargy, difficulties in concentration, social withdrawal, impairment in functional abilities and performing activities of daily living, poorer self-reported health, impaired self-management of disease exacerbations, and poor health behaviors. 52, 70, [86] [87] [88] [89] [90] [91] The correlation between depressed mood and disease severity is modest; 21 but depression symptoms are important correlates of perceived selfreported physical disability and poorer quality of life. 85 Guilty feelings stemming from the sense of burden patients impose to their environment, in combination with the responsibility they might think they have for the occurrence of the disease, especially concerning ex-smokers, aggravates depressive symptomatology. 92 According to studies, clinically significant levels of depression and anxiety were more prevalent in younger COPD patients, irrespective of clinical severity of COPD, perhaps because younger patients may find it difficult to come to terms with enforced changes in lifestyle, with this leading to increased psychological morbidity. 93 Recent studies suggest that depression in patients with COPD is a heterogeneous entity with multiple contributing etiologies including genetic predisposition, environmental losses and stressors, and direct damage to the brain mediated by the physiologic effects of chronic respiratory disease. 94 The genetic vulnerability plays a role in the eventual development of COPD in that adolescents and young adults who are depressed or have a history of depression are more likely to progress in their use of and dependence on nicotine. 54, 55, 96 Smoking, COPD, and depression form a dynamic model of circular causality, with depression playing a role in the initiation and maintenance of smoking, smoking leading to the development of COPD, and COPD in turn contributing to the genesis of depression. 94 Evidence suggests that the appearance of major depression or depressive symptomatology in patients suffering from a chronic disabling general medical condition is common and justified as a "reaction" to the losses imposed by the illness in both symbolic order and real grounds. 97 These losses may include functional impacts 98 such as inability to carry out prior occupational activities, shifted roles within the family, and social constellation, but also an insult to self-image that patients experience with the change in their general physical condition and somatic functioning. 94 Losses for patients with COPD increase with the gradual deterioration of the disease. Dyspnea 65, 99 is the most common and disabling symptom experienced by COPD patients and is inextricably associated with feelings of despair, helplessness, and alienation, resulting in the apparent loss of interest for life and other people.
By the very nature of the disease process, COPD is associated with chronic, if often subclinical, hypoxemia. Low arterial oxygen saturation has been shown to be associated with periventricular white matter lesions, 100 which are also present in elderly patients with depression. 101 Several authors have investigated the relationship between chronic hypoxemia and neuropsychological function, and the consequences of chronic hypoxemia include both impaired cognitive function and depression. 102, 103 Most studies of hypoxemia and depression arise from the sleep apnea literature where one of the primary identified sequelae of recurrent nocturnal hypoxemia is depressed mood. 104 Both depression and COPD have been associated with processes that jeopardize the microvasculature of the brain, 105, 106 and there is evidence for systemic inflammation and elevated biomarkers of oxidative damage. 107 
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Strategies to improve anxiety and depression in patients with COPD there are difficulties in quantification of inflammatory biomarkers, sTNFR-1 has shown a strong association with rates of depression in COPD patients. 108 In the absence of prior comorbidity, systemic inflammation in COPD may result in depression and IL-6 appears to play a particularly important role in humans and in animal models of depression. 109 A prospective cohort study indicated that the mean time elapsed between the diagnosis of COPD and the first episode of depression was 7.6 years. 110 The long-term use of systemic corticosteroids has also been related to depression in COPD, but results are inconclusive. 111 Although smoking, hypoxia, and inflammation have potential impact on the prevalence of depression in COPD, the strongest predictors of depression among patients with COPD are their severity of symptoms and reported quality of life. 33 The advantage to recognizing the interdependent relationship of these contributing factors is the corollary recognition that effective intervention in any one of them will have a cascading, positive impact on the others. Effectively targeting depression, lost functionality, or chronic hypoxemia will decrease morbidity in that dimension, and potentially in the others as well.
Treatment
Despite high prevalence rates and deleterious impact of comorbid anxiety and depression in COPD, only a limited number of studies have addressed its management, 26 accounting for the absence of recommendations regarding their treatment in the updated GOLD guidelines. 1 Only pulmonary rehabilitation (PR) is suggested as treatment option (evidence A), which is also available for only a small percentage of patients. 112 The National Institute for Health and Care Excellence (NICE) has published clinical guidelines for the use of stepped approaches to psychological and/or pharmacological treatment of depression in people with long-term conditions. 113 In recognition of the expanding knowledge and the clinical importance of this area, we attempted to summarize existing empirical evidence based on studies implementing pharmacological and nonpharmacological interventions to reduce clinical anxiety and depression in people with COPD.
Method
A literature search was conducted for studies examining the effect of anxiolytic and antidepressant medical treatment, cognitive behavioral therapy (CBT), PR, and other complex interventions on anxiety and depressive symptoms in COPD patients, using PubMed databases. Essential keywords were "chronic obstructive pulmonary disease" OR "COPD" AND "anxiety" OR "depression" to capture the target population. Intervention search terms comprised "medication" OR "pharmacological treatment" OR "SSRIs" OR "antidepressants" OR "TCAs" OR "SNRIs" OR "mirtazapine" OR "buspirone" OR "benzodiazepines" OR "psychological interventions" OR "cognitive behavioural therapy" OR "psychotherapy" OR "pulmonary rehabilitation" OR "group therapy" OR "complex interventions" OR "relaxation" OR "health education" OR "counselling" OR "behavioural interventions" OR "alternative treatments" OR "Tai Chi" OR "yoga".
Eligibility criteria
Studies for inclusion were required to be in the English language and meet participant, intervention, comparator, and outcome criteria, 114, 115 for studies of controlled comparative design. We also included nonrandomized studies such as clinical trials, crossover studies, observational studies, and relevant review articles and meta-analyses. Participants were adults (men and women of age 18 years), with a confirmed diagnosis of COPD as defined by the GOLD standard, who were treated for symptoms of anxiety and depression. Mode of interventions was pharmacological and nonpharmacological, and was aimed at reducing symptoms of anxiety and depression. The primary outcomes of interest were reduction in these symptoms following the administration of these interventions. The outcome was measured by changes from baseline anxiety and depression scores to posttreatment scores, employing validated psychological assessment instruments.
Quality assessment
The quality of included controlled comparative design studies was assessed by two authors independently with respect to the Critical Appraisal Skills Program checklists for risk of bias evaluation. 116 The methodological quality of full-text articles was assessed employing checklists from the Scottish Intercollegiate Guidelines Network. 300
Results
Electronic database searches yielded 637 records with 438 remaining after removal of duplicates. From the initial title screenings, 253 potentially relevant articles were identified and their abstracts were subsequently reviewed. Of these, 167 were excluded as they failed to meet inclusion criteria. Seventy-two studies and 14 reviews were retrieved in full text for further assessment. 
Overview and effects of pharmacological and nonpharmacological interventions on anxiety and depression in COPD
Pharmacological treatment
Management of depression and anxiety in COPD patients starts with the correct diagnosis. Many patients suffer transitory mood symptoms during respiratory exacerbations and there is no evidence that these time-limited symptoms require specific treatment. NICE guidelines 117 advise that antidepressants should not be routinely prescribed for physically ill patients with subthreshold symptoms of depression or mild-to-moderate depression. Pharmacological therapy must be considered when major depression is diagnosed to avoid its long-term effects on overall disability. 17, [118] [119] [120] A recent study in USA reported that less than a third of COPD patients with major depression received appropriate treatment. 121 The importance of routine screening in COPD patients for depressive symptoms is considered paramount in order to initiate the most appropriate treatment (especially after acute exacerbations and when changes occur in patients' circumstances). 122 All antidepressants have similar effectiveness but mainly differ based on type and severity of side effects. Based on which chemicals in the brain they affect, the main categories are tricyclic antidepressants (TCAs), tetracyclic antidepressants, monoamine oxidase inhibitors, reversible inhibitors of monoamine oxidase, selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors, noradrenergic and specific serotonergic antidepressants, norepinephrine and dopamine reuptake inhibitors, and melatonergic antidepressants.
The choice of antidepressant depends on the pattern of depression, 123 and it is useful to differentiate between early-and late-onset depression, 94 because there is a distinct symptom profile that necessitates diverse treatment strategies. Late-onset depression or geriatric vascular depression after COPD diagnosis, caused by physiologic changes associated with COPD that have direct effect on brain's vasculature, is characterized by more cognitive dysfunction, physical disability, limited insight, and psychomotor 
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Tselebis et al retardation and necessitates support networks and protection against continuous vascular damage. Late-onset depression has been found to be more refractory to treatment with antidepressants, 124, 125 associated with a greater degree of patient apathy, 126 and less often associated with a family history of depression. 127, 128 On the other hand, early-onset depression is defined as depression that develops prior to the diagnosis of COPD, often during an individual's youth. This type of depression is often reflective of a genetic vulnerability to depression, which increases adolescents' risk for developing addiction to nicotine and presents with more classic symptoms, but might have greater difficulty with smoking cessation. 129, 130 It is also necessary to consider that the prescribed medications should not cause sedation or respiratory depression in patients with chronic respiratory conditions. Plus, the ideal medication should have a low side effect profile, a short half-life with no active metabolites, 8 and provoke few drug interactions, especially when considering the other already administered medications for COPD. 131 The most commonly used agents in COPD are β 2 -adrenergic agonists and anticholinergic medication. β 2 -adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Thus coadministration with some SSRIs and TCAs that can prolong QT interval may result in additive effects and increased risk of ventricular arrhythmias. Also, the anticholinergic action of TCAs may be added to that of anticholinergic bronchodilators used in COPD.
Besides pharmacodynamics, pharmacokinetic interactions should be considered, and hence medications with the lowest potential to interfere with cytochrome P450 system should be considered. 132 In general, antidepressants seem to have little effect on ventilator drive, but caution should be taken while prescribing certain antidepressants (TCAs and mirtazapine) in COPD patients with hypercapnia. 112, 133 On the contrary, benzodiazepines may cause respiratory depression and should be avoided, especially for patients with COPD who are CO 2 retainers. 134, 135 A recent prospective study 136 evaluating the safety of benzodiazepines and opioids in patients with very severe COPD indicated that concurrent use of benzodiazepines and opioids in lower doses (0.3 defined daily doses per day) was not associated with increased admissions or mortality, whereas higher doses (0.3 defined daily doses per day) might increase mortality. Additionally, β-blockers are contraindicated in these patients, despite their anxiolytic effect due to their potential risk of bronchoconstriction. 73 Low-potency atypical antipsychotics in very small dosages may alleviate anxiety symptoms in these patients, but should be used with caution as they can have potential neurological and cardiovascular side effects. 26 Small, placebo-controlled trials of antidepressant drug therapy in patients with COPD did not demonstrate significant treatment effects, with the exception of one study, in 1992, 137 which indicated high efficacy for nortriptyline in improving short-term outcomes for depression, anxiety, cognitive function, and overall disability. Other TCAs have been tested, such as doxepine, 138 imipramine, and amitriptyline, [139] [140] [141] [142] with contradictory results. More recent studies [143] [144] [145] [146] [147] have used SSRIs, the current first-line medications for the management of depression, but most suffered from methodological flaws. In few randomized, double-blind, placebo-controlled studies, sertraline, 145,146 fluoxetine, 143, 148 citalopram, 149 and paroxetine 147 offered improvements in quality of life, dyspnea, and fatigue. Start-up side effects with SSRIs include gastrointestinal upset, headache, tremor, and either psychomotor activation or sedation, which is frequently problematic in COPD patients. Treatment timelines necessitate checking the tolerance of medication during 1-3 weeks, then evaluating the response during 2-4 weeks, and if there is response, it is important to complete symptom resolution and move on to continuation and then maintenance phase. In case there is none or inadequate response, augmenting strategies are advised or change of medication is required. 14 Either way, it is necessary to consult a psychiatrist 150 in cases of suicidal or self-injurious behavior, psychotic or bipolar depression, or other psychiatric comorbidities (eg, substance abuse, personality disorders). The presence of complex psychological issues, multimorbidity, frailty, and polypharmacy also necessitates integrated and comprehensive approach for the care of these people. 151 Concerning anxiety, several studies have investigated the effectiveness of specific medications 152 with contradictory results for buspirone 153, 154 and inconclusive results for SSRIs, even though they are better tolerated and can relieve symptoms of panic, 145, 146 but compliance may be poor. 143 A recent Cochrane review 155 on pharmacological interventions for the treatment of anxiety in COPD patients analyzed four studies and found insufficient evidence of benefit for any of medications included. Two studies using SSRIs showed a nonsignificant reduction in anxiety symptoms, 144, 156 while two other studies using TCA and azapirones did not show any improvement. 138, 154 Anticonvulsants such as gabapentin have also been prescribed for the treatment of anxiety symptoms in COPD patients. 73 Some authors report 143, 157 that patients with COPD and psychiatric comorbidity are reluctant to take yet another Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
Dovepress
317
Strategies to improve anxiety and depression in patients with COPD medication, possibly because of stigma associated with the disease or denial, and as mentioned before, data supporting the efficacy of medication-only treatment are extremely limited. 158, 159 When implementing treatment strategies for COPD patients, it is important to remember that there is a greater possibility for medical comorbidities, increased risk for medication interactions, and greater physical debilitation than the community population. 160 An overview of studies on pharmacological treatment for anxiety and depression in COPD patients is summarized in Table 1 .
Psychotherapeutic interventions
Patients prefer nondrug treatments, 161 and clinical guidelines 117, 162 promote nonpharmacological interventions as first-line therapy for depression and anxiety in people with long-term conditions. NICE recommends use of low-(eg, self-help programs) or high-intensity (individual or group CBT) psychosocial interventions depending on the severity of mood symptoms. 163 Both individual and group therapy psychological interventions are useful in promoting more adaptive coping in COPD patients. 92 CBT Evidence suggests that individualized or group CBT is the treatment of choice for addressing the maladaptive coping in the COPD patient with mental health difficulties, because of the time-limited and action-oriented nature of the intervention. 164 According to this psychotherapeutic approach, emphasis is given to the effect of cognitions on mood and behavior. This model of psychotherapy assumes that maladaptive, or faulty, thinking patterns cause maladaptive behavior and "negative" emotions. Maladaptive behavior is behavior that is counterproductive or interferes with everyday living. 14 The treatment focuses on changing an individual's thoughts (cognitive patterns) in order to change his or her behavior and emotional state. Therapists attempt to make their patients aware of these distorted thinking patterns, or cognitive distortions, that fuel anxiety and depressive symptoms and change them (a process termed cognitive restructuring). 14 Therapy focuses on helping patients discover alternative solutions and promote more adaptive coping styles in order to overcome adversities and effectuate operational techniques to address their problems. [165] [166] [167] Mental health guidelines recommend CBT as the treatment of choice for a range of mood and anxiety disorders and as an adjunct to other treatments. Low-intensity CBT-based psychosocial interventions are recommended for people with mild-to-moderate anxiety and/or depression, whereas high-intensity psychological interventions using CBT in combination with medication is recommended for people with moderate-to-severe depression. 162, 163 Not all aspects of CBT may be necessary to produce a therapeutic effect. Purely behavioral interventions can be as effective as CBT for patients with depression. 168 Some studies report that there is potential for psychological interventions to reduce anxiety and depression in people with COPD. 169, 170 A recent meta-analysis of four CBT studies for anxiety and depression in COPD patients indicated improvements in these symptoms. 171 Also, based on randomized controlled trials, CBT resulted in improvement in symptoms of anxiety and depression ( Table 2) , especially when used with exercise and education. 172
Group psychotherapy
Group psychotherapy is a financially attractive approach in response to the realities of limited resources, regardless of its theoretical orientation, because it involves fewer therapists, less therapist per person-hours, and serves more patients.
The group context and group process, if explicitly utilized within the principles of system dynamics, offers valuable healing opportunities. 14 Therapeutic principles, 173, 174 termed "therapeutic" factors, include the experience of relief from emotional distress through the free and uninhibited expression of emotion, feeling a sense of belonging, acceptance, and validation. Within a context that reflects the individual's perception of reality, group members share experiences and feelings and develop social skills through a modeling process.
The therapist's interventions facilitate group activities by taking advantage of the inherent assets of the team, ensuring that it runs efficiently with appropriate boundaries being maintained. 14
Relaxation therapy and alternative treatments
Relaxation therapy encompasses a range of techniques such as breathing exercises, sequential muscle relaxation, biofeedback, guided imagery, distraction therapy, hypnosis, meditation/mindfulness, and physical posture therapy. 175, 176 Often, some of these techniques are components of PR or are used as an adjunct to other therapies (eg, CBT). 112 The purpose of this therapy is to promote psychological change by effectively managing physiological changes accompanying anxiety. In other words, regulation of the sympathetic nervous system and management of the stimulation of certain regions Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
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Tselebis et al of the hypothalamus facilitate the relaxation response. 177 In this perspective, relaxation techniques are often used to inhibit anxiety, increasing the patient's perception of selfcontrol or modulating his or her emotions, in order to promote the perceived well-being of the subject.
A meta-analysis of trials with relaxation-based therapies for COPD patients indicated statistically significant beneficial effects on both dyspnea and psychological well-being. 178 Another recent meta-analysis on the effects of relaxation techniques, of 25 randomized controlled trials including both inpatients and outpatients with COPD, showed a minor positive effect on respiratory function as well as a slight effect on levels of both the anxiety and depression. The higher effect size was found in the quality of life value. 176 Several other studies have investigated other types of relaxation approaches. 179 In a pilot study, the authors argued that the introduction of Tai Chi exercises was worth exploring in patients with COPD, 180 while in another study, 181 Yoga exercises were performed. Singing lessons have also been used as an intervention in patients with COPD. 182, 183 The basic theory is that singing lessons could improve quality of life or functional status in these patients. 184 Regarding these less traditional interventions, there is still lack of certainty about their applicability, their long-term effectiveness, the active component (physical or psychological), and how they can be incorporated into standard care. 185 An overview of studies on relaxation therapies and alternative treatments for anxiety and depression in COPD patients is summarized in Table 3 .
PR
Treatment strategies include PR, because it improves patient's ability to participate in stress-reducing activities and increases their sense of self mastery. It also improves quality of life by increasing patients' perception of available social supports. 186 According to the American Thoracic Society and the European Respiratory Society, PR 187 is an evidence-based multidisciplinary and comprehensive intervention for patients with chronic respiratory diseases who are symptomatic and often have decreased daily life activities.
The ideal patient for PR is one with functional limitations, moderate-to-severe lung disease, who is stable on standard therapy, without comorbid serious or unstable medical conditions, willing to learn about the disease, and motivated to devote time and effort necessary to benefit from a comprehensive care program. 188 The interdisciplinary team of health-care professionals in PR may include physicians, nurses, respiratory and physical therapists, psychologists, and exercise specialists. 151 PR programs operate by means of progressive exercise, training of respiratory function, and psychoeducation, so that patients obtain better exercise tolerance with less dyspnea. The goal is to restore the patient to the highest possible level of independent function. 189 Patients are educated about their disease and learn breathing techniques to reduce air hunger and exercises to optimize oxygen use, and this in turn improves exercise tolerance. Key outcomes such as exercise capacity and overall health-related quality of life may be accurately measured. [190] [191] [192] Exercise-based PR programs have been the most consistently helpful interventions for minor mood symptoms in COPD patients, [193] [194] [195] but the greatest improvements in anxiety and depression are usually in those with the highest scores at baseline. 196 The paradox is that patients most likely to benefit from PR appear least likely to complete it. 197, 198 It is important therefore to be able to identify patients with COPD who may need additional support to complete a PR program in order to broaden benefit to all.
Several mechanisms have been hypothesized to explain the effect of exercise rehabilitation on mental health symptoms. Biological mechanisms associated with exercise activity include changes in central monoamine function, [199] [200] [201] [202] [203] [204] enhanced hypothalamic-pituitary-adrenal axis regulation, increased release of endogenous opioids, [205] [206] [207] and reduced systemic inflammation. 208, 209 In this way, regular physical activity may reduce depression and anxiety among patients undergoing PR. In addition, behavioral mechanisms [210] [211] [212] [213] [214] [215] associated with exercise activities operate synergistically to produce reductions of symptoms. Such mechanisms include active distraction from worrying thought patterns (rumination), increase of self-efficacy by providing patients with a meaningful mastery experience, and provision of daily pleasant events and regular social contact and support.
A recent systematic review 216 showed that PR is beneficial in reducing anxiety and depressive symptoms, but the longterm benefit is unknown. Studies combining antidepressant pharmacotherapy or psychotherapy indicated more effective results than PR alone. 217, 218 Because both depression and anxiety may be manifested in physical symptoms during the course of a PR program, collaborative care is essential among all involved health-care professionals to ensure that patients' problems are identified, evaluated, and treated.
The majority of PR programs have a primary exercise focus in order to recondition the legs and other peripheral muscles, making them more efficient as to oxygen needs, and thereby requiring relative less breathing to satisfy these oxygen requirements. 219 
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Strategies to improve anxiety and depression in patients with COPD breathing control exercises to patients and educate them in recognizing an impending dyspnea attack and preventing it, or controlling it, so they lose their fear of exerting themselves. 220 In PR settings, patients learn that they can have increases in activity levels and in dyspnea without perceiving that increase in dyspnea as a medical crisis. When patients experience their symptoms safely, they become desensitized by learning to distinguish between physical and emotional symptoms. Then, these patients can gradually take responsibility for the day-to-day management of their condition, with a result of improving their confidence, control, and autonomy. 221 PR should be offered to all COPD patients irrespective of disease severity, since they all get improvements, 222, 223 from mild COPD 224 to severe-to-very severe lung disease. 225, 226 Emphasis should be given to exercise training with respect to patients with mild-to-moderate disease, but for patients with severe-to-very severe COPD, PR programs should be tailored mostly toward dyspnea management and psychological support. 227, 228 In sum, the preponderance of recent evidence supports the utility of PR for reducing depression and anxiety and enhancing cognitive performance, but it is necessary to maintain the physical activity regimen to sustain the gains in physical fitness, mood, and cognitive performance, otherwise a relapse is inevitable. 193 Representative studies with PR programs for COPD patients are summarized in Table 4 .
Discussion and recommendations
Mental health problems in COPD remain underdiagnosed and undertreated. 229 Although more than one-third of individuals with COPD experience comorbid symptoms of depression and anxiety, 230 available evidence suggests that less than onethird of COPD patients with such comorbidity are receiving appropriate treatment for this. 231 Every clinician caring for patients with COPD should have a high level of suspicion regarding the presence of mental health comorbidities since they are associated with poorer outcomes. 230 The first step to improve practice is to achieve earlier and more accurate diagnosis. It is not clear when screening should be done 232, 233 and if it should be carried out with all COPD patients or just to those at higher risk of these comorbidities. 29 Current screening tools for anxiety and depression in patients with COPD were primarily validated for patients with other chronic diseases. [234] [235] [236] [237] The Hospital Anxiety Depression and the Beck Depression and Anxiety Inventory scales have been recommended as the preferable choice of screening tools for anxiety and depression in patients with COPD. 29 Clinicians should be aware of the somatic overlap between anxiety and/or depression and COPD. 238, 239 Mild-to-moderate symptoms of anxiety and/or depression should not be ignored, and treatment should be considered. High-scoring patients should be referred to a mental health specialist for a comprehensive diagnostic assessment using structured clinical interviews. It is well known that physiological, functional, and psychosocial consequences of COPD are only poorly to moderately related to each other. 240 This means that a comprehensive assessment of the effects of COPD requires a battery of instruments that not only tap the disease-specific effects, but also the overall burden of the disease on everyday functioning and emotional well-being. Accurate assessment will ensure that treatment modalities are targeting the specific mental health problem taking into account individual factors, such as genetic predisposition, nicotine addiction, social support, other comorbidities, etc.
Identification of mental health problem should guide the choice of pharmacological, psychotherapeutic, or other suitable intervention (Figure 1 ). While treatment guidelines highlight the importance of recognizing and treating depression and anxiety in patients with COPD, there are few clear evidence-based pathways for the treatment of depression and anxiety. A GOLD report states that there is no evidence that anxiety and depression should be treated differently in the presence of COPD, so at this point of time guidelines are based on treatment of depression and anxiety for the general population. 1 In clinical practice, bidirectional associations between depression and/or anxiety and COPD imply the need to promote approaches that integrate physical and mental health care. The NICE has published clinical guidelines for managing depression in people with long-term conditions. 113 The guidelines review the evidence for the associated servicelevel interventions (such as stepped care and collaborative care) and psychosocial, psychological, and pharmacological interventions.
According to reviews and meta-analysis, 185,230 current evidence for treatment options to reduce anxiety and depression in patients with COPD include pharmacological treatments, CBT, PR, relaxation therapy, and personalized interventions. 241, 242 PR has extensive evidence supporting its benefits, and it has been shown to significantly reduce symptoms of both anxiety and depression in COPD patients. 216 Although there is lack of strong evidence for the efficacy of pharmacological treatment in patients with COPD with comorbid depression and anxiety, adding a depression-or anxiety-targeted treatment to the PR Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
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Tselebis et al program may have additive therapeutic benefits. 225 Maximizing the efficiency of services is important as limited health resources allocated to PR programs mean that not every patient with COPD who might benefit has access to them.
In recent years, a model of care termed the collaborativecare model has been found to be associated with significant improvement in depression outcomes. [243] [244] [245] Collaborativecare models that focus on building partnerships between mental health and other professionals to foster integration of care for people with complex morbidities present a fruitful framework for the management of mental health in COPD. 29 By definition, PR is an example of a collaborative-care model. In particular, the integration of PR and psychological therapies, such as CBT, has the potential to lead to significant patient benefits. 230 Contemporary research suggests that complex psychological and/or lifestyle interventions, which include a PR component, have the greatest effects on depression and anxiety in patients with COPD. 246 Most people with stable COPD are managed in primary care where recognition, assessment, and initial management of anxiety and depressive symptoms can be provided. 229 Tailoring mental health interventions to adapt not only to the unique needs of COPD patients but also to the current primary care setting is necessary. From the earliest consultations, we should acknowledge patients' beliefs about their COPD and its management to better assess their likely responsiveness to treatment. We can then more effectively deliver from a menu of interventions in order to improve outcomes. Continuity of care implies that when COPD patients need hospitalization for the treatment of exacerbations, mental health issues should be more systematically addressed enhancing benefit for the many not the few.
Limitations
Including nonrandomized studies and other reviews and meta-analyses resulted in differences to varying degrees from the typical intervention review. Reporting results in narratives impeded the drawing of statistical conclusions about the interventions' summary effect.
Future needs
Future research studies should focus on: 1. Identifying which components of PR are essential, its ideal length and location (hospital-based inpatient or outpatient, or community-based, home-based), the degree of supervision and intensity of training required, how long treatment effects persist, and the barriers of PR attendance and completion in real-life PR settings. 
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Strategies to improve anxiety and depression in patients with COPD 2. Determining the best treatment for specific COPD groups, eg, based on sex, severity of COPD, frequency of exacerbations, and type and severity of comorbid mental health problems, so the efficacy of treatments in different subgroups can be assessed. 3. Disentangling the contributions of exercise training, education, and CBT in a COPD population with clear inclusion and exclusion criteria for anxiety and depression severity and adequately powered RCTs. 4. Investigate a range of treatment options in COPD across all care settings, including comparison of different treatment options and various combinations. 5. Address the cost-effectiveness and feasibility of targeted treatment of anxiety and depression, of the different interventions (eg, optimal length of therapy; when to stop treatment in nonresponders; identifying predictors of success and failure). 6. Examine novel types of disease management interventions with respect to social and behavioral principles and models most relevant for COPD patients in order to increase their engagement and improve health outcomes. 247,248 7. Develop properly "evidence-based" COPD care programs that proactively address mental health in order to optimize physical and mental health outcomes.
Conclusion
Patients suffering from COPD frequently experience comorbid symptoms of anxiety and depression. Detection and recognition of these symptoms is of utmost importance as they are related to both disease progression, treatment, and rehabilitation procedures. Although the literature on treating anxiety and depression in COPD patients is limited, we believe that it points to a more multidisciplinary approach and to the implementation of personalized strategies to address both anxiety and depressive symptoms in these patients.
